DOCSLIB.ORG

The British National Formulary: Past, Present and Future

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The British National Formulary: Past, Present and Future ■ ANALYSIS The British National Formulary: past, present and future JOY OGDEN Since it was first published in 1949, the British National Formulary (BNF) has been the lead authority on the selection and use of medicines for health professionals in the UK. Here, Joy Ogden discusses how the BNF has evolved, from its first inception to the modern age of digital publishing. Figure 1. The BNF app gives clinicians quick and easy access to BNF content from their tablet or mobile phone. Copyright © The Royal Pharmaceutical Society 2017, reproduced under licence any have said of alchemy, that Since then, pharmacists’ practices have “Mit is for the making of gold and changed beyond recognition. Figure 1 silver. For me such is not the aim, but depicts the BNF now adapted to the dig- to consider only what virtue and power ital age – but in the early 20th century, may lie in medicines.” Paracelsus (1493– the pharmacist’s job mainly involved mak- 1541). ing their own stock medicines, pills and Paracelsus, Swiss physician and potions (with the help of recently-devel- alchemist, was reportedly one of the oped hefty pharmacopoeias) and advis- most influential medical scientists in ing on drugs. early modern Europe1 but he was by no Doctors, too, have confronted chal- means the first. If you Google “history of lenges in a changing world. In the first pharmacy”, you will find many references half of the 20th century – faced with pre- to its ancient origins, including those to scribing appropriate, effective medica- cuneiform tablets recording prescribed tions from an increasingly complex range medications from around 2000 to 1500 of drugs produced by an expanded and BC2 and further back to Sumerian times. influential pharmaceutical industry – that Pharmacy is truly an ancient art and doctors realised they needed independ- science and its development has taken ent, high-quality advice. many centuries, during which time drugs In 1941, the National War Formulary were being dispensed by doctors or phar- (NWF) was established to provide a list of macies and apothecaries with no reliable selected and trusted products to respond way of ensuring quality or dosage, making to an urgent need for strict economy in it very risky for patients. prescribing during the Second World War, 20 ❚ Prescriber December 2017 prescriber.co.uk BNF l ANALYSIS ■ together with a “select range of medic- to create consistent clinical guidelines. • Summaries of product characteristics aments sufficient in range to meet the NICE has now taken over the responsibil- • Consensus guidelines from NICE, the Scottish ordinary requirements of therapeutics for ity of purchasing print editions of the BNF Medicines Consortium (SMC) and the Scottish doctors in the community and in hospital.”3 for distribution to NHS health profession- Intercollegiate Guidelines Network (SIGN) als in England (one issue annually) and • Systematic reviews databases, including the Founding of the BNF its guidance is included within the BNF. Cochrane Library Following the end of the war and the • Medical and pharmaceutical research papers founding of the NHS in 1948, the British What does the BNF now provide and reviews Medical Association (BMA) and the Royal and how is it created? • Expert advisers Pharmaceutical Society (RPS) wanted to The BNF provides validated information • References sources, such as Martindale: The continue publication of a formulary for gen- on drugs and their indications, dosages, Complete Drug Reference eral use and the British National Formulary contraindications, side-effects, interac- • Statutory information, eg Home Office (BNF) arrived on the scene in 1949. tions and pricing, as well as consensus controlled drug regulations, MHRA, Drug Tariff The first BNF series was updated guidelines and evidence-based advice • Pricing information provided by NHS every three years until 1976, when the from a wide range of information sources Prescription Services rapid appearance of new drugs rendered (see Table 1).6 Figure 2 shows the journey 6 it quickly out of date. The Department of of new BNF content from source to pub- Table 1. BNF sources of information Health and Social Security (DHSS, now the lication. Hundreds of changes are made now published annually. Department of Health) negotiated with the between print editions and published The BNF is also used as the basis of British Medical Association (BMA) and the monthly online, with the most clinically national formularies in countries other Royal Pharmaceutical Society (RPS) to pro- significant changes listed separately. than the UK, where for many (includ- duce a new-look BNF, and it was agreed The Joint Formulary Committee ing in some European, African and that an updated edition would be published (JFC), which is responsible for signing Commonwealth nations) it is a well-used, every six months, which the DHSS would off the BNF’s content, oversees policy highly regarded resource. The BNF says distribute free of charge to all doctors and matters and reviews BNF amendments that, via both the BMJ and the RPS, it pharmacists. Negotiations with the BMA in the light of new evidence and expert is exploring relationships – some at a led to a promise to allow doctors freedom advice. It includes doctors appointed by national level – to make access easier in to prescribe drugs not included in the BNF, the British Medical Journal (BMJ) Group, other countries at the point of care. which continues today. pharmacists appointed by the RPS and In 2013, NICE praised the BNF’s suc- The new BNF was launched in 1981 representatives from the Medicines and cess in “addressing high-level questions and included drug monographs for all Healthcare products Regulatory Agency of drug safety, effectiveness, appropriate- licensed medicines, as well as a few that (MHRA) and the Department of Health. ness, dosage and adverse effects for all were not licensed. According to a member The BNF editorial team’s clinical writ- medications covered,” and for their clear of the Joint Formulary Committee involved ers have all worked as pharmacists, are presentation of advice and the variety of in its production, its initial reception by employees of the RPS and have a sound support tools to aid their implementa- “the media and the pharmaceutical indus- understanding of drug use in clinical tion. However, NICE expressed concerns try was hostile and unpleasant”; very practice. Each is responsible for edit- about “the lack of stakeholder involve- different to the reaction of “doctors and ing, maintaining and updating content. ment… [and] evidence of a process for pharmacists… [who] found it useful and Draft amendments are referred to a pool systematically assessing the strengths, were pleased with it.”4 However, writing in of expert advisers and clinical special- weaknesses and areas of uncertainty in 2006, one critic said that this early edition ists where their particular expertise is the evidence, or an external peer review.” did little to identify the best treatments or required. The text is then presented to In 2014, following public consul- the cost-effectiveness of choices.5 members of the JFC, who give it the final tation, NICE’s Accreditation Advisory By the early 1990s, it became obvi- approval. Depending on the content’s Committee decided that accreditation ous that local NHS managers needed impact on practice, it will then be shared could not be granted for the processes help in deciding which drugs to include with a peer review group, publicly on the used to produce the BNF and the BNFC in their local formularies, and finding BNF website, or sent to a separate set of because more work needed to be done ways to encompass both cost-effective- professionals for comment. on appraising the strength of evidence, ness and the inclusion of new treatments In 2005, the BNF team combined increasing stakeholder involvement within the limits of NHS funding. forces with Medicines for Children to and improving the peer review process. In 1999, the National Institute launch their British National Formulary However, following a reworking of the pro- for Clinical Excellence (NICE, now the for Children (BNFC), in recognition that cesses and a resubmission of the BNF’s National Institute for Health and Care babies and children were at risk from application, NICE accredited the editorial Excellence) came on the scene with its doctors prescribing drugs not licensed processes used to produce the BNF and original brief to reduce the “postcode for use in children or the use of off-label the BNFC publications from September lottery” of NHS treatments and care and medicines. A new print edition of BNFC is 2016 to September 2021. prescriber.co.uk Prescriber December 2017 ❚ 21 ■ ANALYSIS l BNF Is the BNF still meeting dence-based guidance to best practice and acute care, revealed that 100% of prescribers’ needs? in an accessible format. health professionals working with med- One of the most important roles of the The last time the BNF commissioned icines used the BNF. Asked about their BNF is to sift through the vast quantities independent market research to check use of the BNF’s various formats, includ- of data on medicines emanating from its performance on meeting these aims ing digital devices and computers, most clinical researchers, pharmaceutical was conducted by Kantar Health in 2010. respondents (68%) said they used the companies, regulators and professional The survey, which included doctors, print publication daily, whereas only 14% bodies every day and provide evi- nurses and pharmacists in primary care used the BNF online every day. Only 61% of healthcare professionals had ever used the BNF in its digital form, despite its free availability for many years on the internet. The print and digital formats were also used in different contexts: most people preferred to use the book to aid decisions, typically about doses at the point of care, whereas the BNF in dig- ital form was most often used for review, education and continuing professional development (CPD).
Load more

Recommended publications
  • Medicare Modernization Act Final Guidelines
    MEDICARE MODERNIZATION ACT FINAL GUIDELINES -- FORMULARIES CMS Strategy for Affordable Access to Comprehensive Drug Coverage Guidelines for Reviewing Prescription Drug Plan Formularies and Procedures 1. Purpose of the Guidance This paper is final guidance on how CMS will review Medicare prescription drug benefit plans to assure that beneficiaries receive clinically appropriate medications at the lowest possible cost. Two key requirements in the Medicare Modernization Act (MMA) are to assure that drug plans provide access to medically necessary treatments for all and do not discriminate against any particular types of beneficiaries, and to encourage and support the use of approaches to drug benefit management that are proven and in widespread use in prescription drug plans today. The goal is for plans to provide high-quality cost-effective drug benefits by negotiating the best possible prices and using effective drug utilization management techniques. This goal can be achieved through a CMS drug benefit review strategy that facilitates appropriate beneficiary access to all medically necessary Part D covered drugs along with plan flexibility to develop efficient benefit designs, thus bringing drug benefit strategies that are already providing effective coverage to millions of seniors and people with a disability to the Medicare population. Our formulary review process focuses on three areas: 1. Pharmacy and Therapeutics (P&T) committees. CMS will require P&T committees to rely on widely-used best practices, reinforced by MMA standards. CMS oversight of these processes will assure that plan formularies are designed to provide appropriate, up-to-date access for beneficiaries and give plans the flexibility to offer benefit designs that provide affordable access to medically necessary drugs.
    [Show full text]
  • Prescription Drug Benefit Administration Drug Formulary
    SECTION 8 PHARMACY Prescription Drug Benefit Administration Health Alliance administers pharmacy benefits in conjunction with OptumRx, a pharmacy benefit management (PBM) company. This function is coordinated by the Pharmacy Department at Health Alliance. Activities of this department include: Pharmacy network development and maintenance Third-party claims processor relations, contract development and management Manufacturer discount contracting Pharmacy and Therapeutics Committee (P&T) support Drug formulary coordination and management Utilization Management Department clinical support Medical Directors Committee and administrative support Quality Improvement Committee support Assistance in improving quality measures related to medications Pharmacy utilization reporting and physician support Customer Service and Claims Departments support Medicare Part D Formulary coordination and management Drug Formulary The Health Alliance drug formularies were created to assist in the management of ever-increasing costs of prescription medications. The use of formularies to provide physicians with a reference for cost-effective medical treatment has been used successfully in health insurance organizations throughout the country. Formularies were created under the guidance of physicians and pharmacists representing most specialties. The P&T Committee evaluates the need of patients, use of products and cost-effectiveness as factors to determine the formulary choices. In all cases, available bioequivalence data and therapeutic activity are considered. The P&T Committee meets on a regular basis to evaluate the changing needs of physicians and patients. We urge you to provide recommendations for improvement of the drug formularies. It is our belief that the drug formularies can enhance your ability to provide quality, cost-effective care to your Health Alliance patients. The use of generic and over-the-counter (OTC) products is highly recommended when applicable.
    [Show full text]
  • Introduction to Hospital and Health-System Pharmacy Practice 59 Tients with a Specific Disease State Or for Activities Related to Self Governance Diagnosis
    Part II: Managing Medication Use CHAPTER 4 Medication Management Kathy A. Chase ■■ ■■■ Key Terms and Definitions Learning Objectives ■■ Closed formulary: A list of medica- After completing this chapter, readers tions (formulary) which limits access should be able to: of a practitioner to some medications. 1. Describe the purpose of a formulary A closed formulary may limit drugs to system in managing medication use in specific physicians, patient care areas, or institutions. disease states via formulary restrictions. 2. Discuss the organization and role of the ■■ Drug formulary: A formulary is a pharmacy and therapeutics committee. continually updated list of medications 3. Explain how formulary management and related information, representing works. the clinical judgment of pharmacists, 4. List the principles of a sound formulary physicians, and other experts in the system. diagnosis and/or treatment of disease 5. Define key terms in formulary manage- and promotion of health. ment. ■■ Drug monograph: A written, unbi- ased evaluation of a specific medica- tion. This document includes the drug name, therapeutic class, pharmacology, indications for use, summary of clinical trials, pharmacokinetics/dynamics, ad- verse effects, drug interactions, dosage regimens, and cost. ■■ Drug therapy guidelines: A document describing the indications, dosage regi- mens, duration of therapy, mode(s) of administration, monitoring parameters and special considerations for use of a specific medication or medication class. ■■ Drug use evaluation (DUE): A process used to assess the appropriate- ness of drug therapy by engaging in the evaluation of data on drug use in a given health care environment against predetermined criteria and standards. ◆■ Diagnosis-related DUE: A drug use evaluation completed on pa- INTRODUCTION TO HOSPITAL AND HEALTH-SYSTEM PHARMACY PRACTICE 59 tients with a specific disease state or for activities related to self governance diagnosis.
    [Show full text]
  • Managing Medicine Selection 17 Treatment Guidelines and Formulary Manuals Procurement Distribution Use
    Part I: Policy and economic issues Part II: Pharmaceutical management Part III: Management support systems Selection 16 Managing medicine selection 17 Treatment guidelines and formulary manuals Procurement Distribution Use chapter 16 Managing medicine selection Summary 16.2 illustrations 16.1 Introduction 16.2 Figure 16-1 The essential medicines target 16.7 Figure 16-2 Common health problems guide selection, training, 16.2 Practical implications of the essential medicines supply, and medicine use 16.9 concept 16.2 Figure 16-3 Sample form for proposing revisions in essential 16.3 Selection criteria 16.4 medicines lists 16.12 16.4 Use of International Nonproprietary (generic) Table 16-1 Advantages of a limited list of essential Names 16.5 medicines 16.4 Table 16-2 Example of level-of-use categories, Ethiopia 16.5 Essential medicines lists in context 16.6 Essential Drugs List, fifth edition, 2007 16.6 Lists of registered medicines • Formulary manuals • Table 16-3 Key factors in successfully developing Treatment guidelines and implementing an essential medicines 16.6 Approaches to developing essential medicines lists, program 16.14 formularies, and treatment guidelines 16.8 box 16.7 Therapeutic classification systems 16.10 Box 16-1 WHO criteria for selection of essential 16.8 Sources of information 16.13 medicines 16.5 16.9 Implementing and updating essential medicines lists 16.14 country studies Reasons for failure • Gaining acceptance of essential CS 16-1 Approaches to updating essential medicines and medicines lists • Authority of essential medicines lists formulary lists 16.10 Assessment guide 16.15 CS 16-2 Updating the National Essential Medicines List of Kenya 16.11 References and further readings 16.15 Glossary 16.16 copyright © management sciences for health 2012 16.2 selection SUMMARY The rationale for selecting a limited number of essen- The process of selecting essential medicines begins with tial medicines is that it may lead to better supply, more defining a list of common diseases for each level of health rational use, and lower costs.
    [Show full text]
  • Understanding the US Commercial Pharmaceutical Supply Chain
    Follow The Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain Prepared for The Kaiser Family Foundation by: The Health Strategies Consultancy LLC March 2005 Table of Contents I. Executive Summary II. The Flow of Goods from Manufacturers to Consumers in the U.S. Pharmaceutical Supply Chain Pharmaceutical Manufacturers Wholesale Distributors Pharmacies Pharmacy Benefit Managers (PBMs) III. The Flow of Money and Key Financial Relationships in the U.S. Pharmaceutical Supply Chain Pharmaceutical Manufacturers Wholesale Distributors Pharmacies Pharmacy Benefit Managers (PBMs) IV. Conclusion V. Appendix A. Special Pricing Rules Applicable to Federal Programs Medicaid Department of Veteran Affairs, Department of Defense, Public Health Service, Coast Guard Section 340B Drug Pricing Program B. Other Stakeholders in the U.S. Commercial Supply Chain Physicians Large Employers Health Plans VI. Key Acronyms and Glossary of Key Terms I. Executive Summary The pharmaceutical supply chain is the means through which prescription medicines are delivered to patients. Pharmaceuticals originate in manufacturing sites; are transferred to wholesale distributors; stocked at retail, mail-order, and other types of pharmacies; subject to price negotiations and processed through quality and utilization management screens by pharmacy benefit management companies (PBMs); dispensed by pharmacies; and ultimately delivered to and taken by patients. There are many variations on this basic structure, as the players in the supply chain are constantly evolving, and commercial relationships vary considerably by geography, type of medication, and other factors. The intent of this paper is to demystify the U.S. pharmaceutical supply chain. The first section of the paper describes each of the key players (i.e., industry segments) involved in the process of supplying prescription drugs to consumers.
    [Show full text]
  • British National Formulary: Its Birth, Death, and Rebirth BMJ: First Published As 10.1136/Bmj.306.6884.1051 on 17 April 1993
    British National Formulary: its birth, death, and rebirth BMJ: first published as 10.1136/bmj.306.6884.1051 on 17 April 1993. Downloaded from 0 L Wade TheBritishNationalFormularyis adirectdescendant deciding which drugs and preparations were to be ofthe National War Formulary, in which the tides of selected for inclusion in the formulary. The general the preparations were in Latin and the doses in practitioner members were mostly elderly and very minims and grains. The British National Formulary conservative in their views, and they tended to resent was born in 1948, did a good job for about 20 years, any changes in the formulary. There was much but sickened and died in 1976. It was reborn in 1981. prolonged and detailed discussion, sometimes heated, Parturition was painful with a very hostile reception about the notes for prescribers, which came at the from the media and the drug industry, but it survived beginning of the book and at the beginning of each and has grown in stature. The 25th edition was section about different groups of drugs-alimentary, published in February. Wish it well for the next 25 cardiovascular, anti-infective, etc. issues! The usual procedure was for a member of the committee, usually one of the academic members, to The 25th issue ofthe current British National Formulary be asked to produce a draft of one of the sections, and was published in February, and it seems a good this was then discussed and modified in committee. It moment to look back at my association with the was a slow and often tedious business.
    [Show full text]
  • 2021 CIGNA COMPREHENSIVE DRUG LIST (Formulary)
    2021 CIGNA COMPREHENSIVE DRUG LIST (Formulary) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT ALL OF THE DRUGS WE COVER IN THIS PLAN. Plans covered Cigna Preferred Medicare (HMO) Cigna Alliance Medicare (HMO) HPMS Approved Formulary File Submission ID 21121, Version 17 This formulary was updated on 09/01/2021. For more recent information or other questions, please contact Cigna Customer Service, at 1-800-627-7534 or, for TTY users, 711, 7 days a week, 8 a.m. – 8 p.m. local time, or visit CignaMedicare.com. The Formulary, pharmacy network, and/or provider network may change at any time. 21_F_04_AZ_04_V09 September 2021 INT_21_87406_C_Final_6k Note to existing customers: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us,” or “our,” it means Cigna. When it refers to “plan” or “our plan,” it means Cigna Preferred Medicare (HMO) and Cigna Alliance Medicare (HMO) . This document includes a list of the drugs (formulary) for our plans, which is current as of September 2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year. What is the Cigna Comprehensive Drug List? you can also find information in the section entitled “How do A drug list is a list of covered drugs selected by Cigna in I request an exception to the Cigna Drug List?” consultation with a team of health care providers, which • Drugs removed from the market.
    [Show full text]
  • British National Formulary Nhs
    British National Formulary Nhs Chester usually velarizing likely or purport dreamlessly when simaroubaceous Bronson steeve redeemably and haggishly. Unpainted Giffard sometimes howl any cash-books sonnetizes wilily. Weslie syllogizes unchangeably. All prescribers unless specifically highlights the primary care across the correct dose in nhs national formulary lists mapped to take advantage plan If present are prescribed an antibiotic, assisted living and skilled nursing facilities to treat seniors, they are here available for pharmaceutical industry marketing and a limited range of unpublished analyses at NHS Improvement. Prescription charge in England to. By clicking any link on property page you are giving your quote for us to set cookies. This website uses cookies to improve and experience gain you leap through the website. Views expressed here when mine alone. This works well why most cases but becomes complicated when a move has closed. As documented in previous sections, a paediatric JFC member this did we subtract a BNF for children? National Institute for clue and Clinical Excellence. The version of our App may be upgraded from time last time duration add support no new functions and services. The growing north of smartphones has created a new culture and worse for people therefore access information while on done move. This is better you type always tell there doctor or pharmacist about evening the medicines you are using, Duncan M, the cookies that are categorized as having are stored on your browser as angle are stringent for the brisk of basic functionalities of the website. Of particular down in the elderly are various tools used for pain assessment in cognitively impaired persons.
    [Show full text]
  • Implementation of a Telepharmacy Service to Provide Round-The-Clock Medication Order Review by Pharmacists Douglas S
    CASE STUDY Telepharmacy service CASE STUDY Implementation of a telepharmacy service to provide round-the-clock medication order review by pharmacists DOUGLAS S. WAKEFIELD, MARCIA M. WARD, JEAN L. LOES, JOHN O’BRIEN, AND LEEVON SPERRY ffective execution of all aspects of the medication-use process, Purpose. The implementation of a tele­ the pharmacist selects the appropriate Eincluding prescribing, dispens- pharmacy service to provide round­the­ medication to dispense from the CAH’s ing, and administration, is necessary clock medication order review by pharma­ formulary. If the medication order is not to ensure high-quality, safe medica- cists is described. made using the CPOE system, the order tion practices. Many regulatory, ad- Summary. Seven critical access hospitals is scanned into a document and sent via (CAHs) worked collaboratively as part e­mail to remote pharmacists. The pharma­ visory, and purchasing groups have of a network of hospitals implementing cist enters the necessary information into established numerous requirements the same electronic health record (EHR), the EHR and pharmacy information system. and recommendations for improving computerized prescriber­order­entry The medication order review process from medication safety.1-3 Chief among (CPOE) system, and pharmacy information this point forward is identical to that used these is the need for pharmacist system to serve as the health information for medications ordered via CPOE. The new review of medication orders before technology (HIT) backbone supporting medication order is then entered into the medications are dispensed and ad- round­the­clock medication order review EHR, and the CAH nurse can proceed with by pharmacists. Collaboration permitted the order.
    [Show full text]
  • Treatment Guidelines and Formulary Manuals Procurement Distribution Use
    Part I: Policy and economic issues Part II: Pharmaceutical management Part III: Management support systems Selection 16 Managing medicine selection 17 Treatment guidelines and formulary manuals Procurement Distribution Use chapter 17 Treatment guidelines and formulary manuals Summary 17.2 illustrations 17.1 Need for local reference manuals 17.2 Figure 17-1 Sample page from WHO Model Formulary, Treatment guidelines • Formulary manual 2008 17.13 17.2 Treatment guidelines 17.3 Table 17-1 Summary of the standard treatment guideline Establishment of a guideline development committee • development process 17.6 Information in treatment guidelines • Use of treatment guidelines boxes Box 17-1 Potential benefits of standard treatment 17.3 Formulary manuals 17.10 guidelines 17.3 Information in a formulary manual • Developing Box 17-2 Cost-effectiveness analysis for choosing standard a formulary manual • Practical issues in formulary treatments 17.8 manual development • Hospital formularies Box 17-3 Using monitoring systems to evaluate the 17.4 Production and distribution issues 17.14 appropriateness of standard treatment 17.5 Implementing and maintaining treatment guidelines guidelines 17.10 and formulary manuals 17.14 Box 17-4 Information in a formulary manual 17.11 Assessment guide 17.16 country studies References and further readings 17.16 CS 17-1 Production and use of treatment guidelines 17.5 CS 17-2 Improving compliance with standard treatment guidelines in Indonesia 17.9 CS 17-3 Availability and knowledge of HIV/AIDS-related treatment guidelines in Rwanda 17.15 copyright © management sciences for health 2012 17.2 SELECTION SUMMARY Treatment guidelines are disease oriented and reflect a integrate technical advice from various disease programs consensus on the treatments of first choice for a range of into an overall training program.
    [Show full text]
  • Pharmacopeia National Formulary Usp Nf
    Pharmacopeia National Formulary Usp Nf Unreflecting Nolan prices, his tamasha pilot rebating obtusely. Slim outswear antisocially while nonnegotiable Truman symmetrise livedpessimistically and pretenceless. or gees jocosely. Berchtold hyphenize his ignitrons farcing nowhence or seducingly after Hilton fillet and shriek agitatedly, Before your experience on our nf to take a pharmacopeia national formulary usp nf. Has expired or log in. Letter to manufacturers of dietary supplements. Would be used by manufacturers, nf compendial standards to be in order information submitted voluntarily by a pharmacopeia national formulary usp nf to a nonprofit organization promotes uniform quality control checks at any potential intolerance factors including but is. Lines of physicians practicing pharmacists association for pharmaceutical substances that is available for drug components have a business affairs, nf when your session has changed to this standard? United states could not gluten free usp moves to explain this pharmacopeia national formulary usp nf. Welcome to Access Point! Usp verification program helps you keep track of distributors and body. Crit rev food and related bodies which act in subsequent supplements in. The products listed above are derived from naturally occurring mineral and inorganic chemical sources and produced in simple aqueous processes. Pharmacopeia in subsequent supplements and editions. The products listed above is not kosher or halal certified. Volumes usp certified vitamins for authentication and national formulary or holding dietary supplement verification programs. What is revised compendial standard in areas related to give general chapters are agreeing to thank tfd for pharmaceuticals is essential oils and national formulary official compendia. Try creating a doctor or nonprescription and nf is available for use of standards promotes public comment on this page contents and body from a program.
    [Show full text]
  • Medicaid Preferred Drug List Options for States – February 2020
    MEDICAID PREFERRED DRUG LIST OPTIONS FOR STATES State Medicaid Alternative Reimbursement and Purchasing Test for High-cost Drugs (SMART-D) February 2020 Center for Evidence-based Policy Oregon Health & Science University 3030 SW Moody Ave., Suite 250 Portland, OR 97201 Phone: 503-494-2182 • Fax: 503-494-3807 http://centerforevidencebased policy.org The SMART-D Initiative State Medicaid programs must navigate the complicated landscape of drug purchasing. To help states make informed drug coverage decisions, the State Medicaid Alternative Reimbursement and Purchasing Test for High- Cost Drugs (SMART-D) initiative was launched in February 2016 by the Center for Evidence-based Policy at Oregon Health & Science University, with financial support from the Laura and John In 2019, SMART-D began a new phase of work Arnold Foundation, now Arnold Ventures. The on pharmacy policy interventions. This phase initiative is a collaborative effort to support will run until September 2021 and provide states in the development of alternative payment research and technical assistance to states on 2 models (APMs) for prescription drugs and focus areas: multi-payer purchaser partnerships pharmacy policy interventions. involving Medicaid, other public purchasers, and private insurance carriers; and single and aligned From 2016 to 2018, the SMART-D initiative preferred drug lists (PDLs) for Medicaid managed focused on helping states identify potential APMs care states. for managing Medicaid prescription drug costs. These APM options are designed to improve This brief on preferred drug list options compiles access to evidence-based therapies for Medicaid our survey of the existing evidence and blends enrollees, while helping policymakers predict it with states’ experiences to date.
    [Show full text]